Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
World game at war: why some European nations have threatened a World Cup boycott 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
WEST LAFAYETTE, Ind., May 01, 2018 -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at Deutsche Bank’s 43rd Annual Health Care Conference being held at the Intercontinental Hotel Boston on Tuesday, May 8th at 1:35 p.m. EDT.
A live audio webcast of the Company's presentation can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte's website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company's website for 90 days following the conference.
Website Information
Endocyte routinely posts important information for investors on its website, www.endocyte.com, in the “Investors & News” section. Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the “Investors & News” section of Endocyte’s website, in addition to following its press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Endocyte’s website is not incorporated by reference into, and is not a part of, this document.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic in 2018, where it will be studied in osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com.
Investor Contact:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
